medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Número 2

Siguiente >>

Rev Mex Urol 2025; 85 (2)


Infección de Virus de Papiloma Humano y cáncer de próstata en México

Rodríguez-Romero BI, Torres-Ramírez DA, Ávila QFM, Sánchez MV

Idioma: Español
Referencias bibliográficas: 32
Paginas: 1-8
Archivo PDF: 251.74 Kb.


RESUMEN

La asociación entre el Cáncer de Próstata (CaP) y la infección del Virus del Papiloma Humano (VPH) ha sido bien documentada en el mundo, pero poco en México. En esta revisión se describen aspectos que vinculan la infección de VPH con CaP y se analizan los reportes realizados en México. El análisis en la mayoría de los reportes demostró asociación, detectando VPH en el 14 % de CaP y en el 8.5 % de hiperplasia prostática benigna; se sugiere realizar más estudios que permitan establecer un papel del virus en la patogénesis para implementar estrategias específicas de prevención en CaP.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tsydenova IA, Ibragimova MK, TsyganovMM, Litviakov NV. Human papillomavirus andprostate cancer: systematic review and metaanalysis.Scientific Reports. 2023;13(1): 16597.

  2. Basulto-Martínez M, Flores-Tapia JP, Conde-Ferráez L, Esuqeda-Mendoza A, KantunMoreno N, Gómez-Carballo J, et al. [Moleculardetection of human papillomavirus amongpatients with benign prostatic hyperplasiaand prostate cáncer.]. Archivos Espanoles DeUrologia. 2022;75(1): 27–33.

  3. Medel-Flores O, Valenzuela-RodríguezVA, Ocadiz-Delgado R, Castro-Muñoz LJ,Hernández-Leyva S, Lara-Hernández G, et al.Association between HPV infection and prostatecancer in a Mexican population. Genetics andMolecular Biology. 2018;41(4): 781–789. https://doi.org/10.1590/1678-4685-GMB-2017-0331.

  4. Dávila- Rodríguez MI, Ignacio- Morales CV,Aragón Tovar AR, Olache-Jiménez, Castelán-Maldonado E, Lara-Miranda S, et al. HumanPapilloma Virus Detection by INNOLiPA HPV inProstate Tissue from Men of Northeast Mexico.Asian Pacific Journal of Cancer Prevention :APJCP. 2016;17(11): 4863–4865. https://doi.org/10.22034/APJCP.2016.17.11.4863.

  5. Martínez-Fierro ML, Leach RJ, Gómez-GuerraLS, Garza-Guajardo R, Johnson-Pais T, BeutenJ, et al. Identification of viral infections in theprostate and evaluation of their association withcancer. BMC Cancer. 2010;10(1): 326. https://doi.org/10.1186/1471-2407-10-326.

  6. Sung H, Ferlay J, Siegel RL, LaversanneM, Soerjomataram I, Jemal A, et al. GlobalCancer Statistics 2020: GLOBOCAN Estimatesof Incidence and Mortality Worldwide for 36Cancers in 185 Countries. CA: a cancer journalfor clinicians. 2021;71(3): 209–249. https://doi.org/10.3322/caac.21660.

  7. Bray F, Laversanne M, Sung H, Ferlay J,Siegel RL, Soerjomataram I, et al. Globalcancer statistics 2022: GLOBOCAN estimatesof incidence and mortality worldwide for 36cancers in 185 countries. CA: a cancer journalfor clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.

  8. Ferlay J, Ervik M, Lam F, Laversanne M,Colombet M, Mery L, et al. Global CancerObservatory: Cancer Today (version 1.1). 2024.

  9. Griffin JE. Androgen resistance--the clinical andmolecular spectrum. The New England Journalof Medicine. 1992;326(9): 611–618. https://doi.org/10.1056/NEJM199202273260906.

  10. Koochekpour S. Androgen receptor signalingand mutations in prostate cancer. Asian Journalof Andrology. 2010;12(5): 639–657. https://doi.org/10.1038/aja.2010.89.

  11. Shorning BY, Dass MS, Smalley MJ, PearsonHB. The PI3K-AKT-mTOR Pathway and ProstateCancer: At the Crossroads of AR, MAPK,and WNT Signaling. International Journal ofMolecular Sciences. 2020;21(12): 4507. https://doi.org/10.3390/ijms21124507.

  12. Taitt HE. Global Trends and Prostate Cancer:A Review of Incidence, Detection, andMortality as Influenced by Race, Ethnicity, andGeographic Location. American Journal of Men’sHealth. 2018;12(6): 1807–1823. https://doi.org/10.1177/1557988318798279.

  13. Bleyer A, Spreafico F, Barr R. Prostate cancer inyoung men: An emerging young adult and olderadolescent challenge. Cancer. 2020;126(1): 46–57. https://doi.org/10.1002/cncr.32498.

  14. Matshela RF, Maree JE, van Belkum C.Prevention and detection of prostate cancer:a pilot intervention in a resource--poorSouth African community. Cancer Nursing.2014;37(3): 189–197. https://doi.org/10.1097/NCC.0b013e31829194d2.

  15. Altwaijry N, Somani S, Parkinson JA, Tate RJ,Keating P, Warzecha M, et al. Regression ofprostate tumors after intravenous administrationof lactoferrin-bearing polypropyleniminedendriplexes encoding TNF-α, TRAIL, andinterleukin-12. Drug Delivery. 2018;25(1): 679–689. https://doi.org/10.1080/10717544.2018.1440666.

  16. Catalona WJ, Smith DS, Ratliff TL, DoddsKM, Coplen DE, Yuan JJ, et al. Measurement ofprostate-specific antigen in serum as a screeningtest for prostate cancer. The New England Journalof Medicine. 1991;324(17): 1156–1161. https://doi.org/10.1056/NEJM199104253241702.

  17. Termini D, Den Hartogh DJ, Jaglanian A,Tsiani E. Curcumin against Prostate Cancer:Current Evidence. Biomolecules. 2020;10(11):1536. https://doi.org/10.3390/biom10111536.

  18. Russo GI, Calogero AE, Condorelli RA, Scalia G,Morgia G, La Vignera S. Human papillomavirusand risk of prostate cancer: a systematic reviewand meta-analysis. The Aging Male: The OfficialJournal of the International Society for the Studyof the Aging Male. 2020;23(2): 132–138. https://doi.org/10.1080/13685538.2018.1455178.

  19. Moghoofei M, Keshavarz M, Ghorbani S, BabaeiF, Nahand JS, Tavakoli A, et al. Associationbetween human papillomavirus infection andprostate cancer: A global systematic review andmeta-analysis. Asia-Pacific Journal of ClinicalOncology. 2019;15(5): e59–e67. https://doi.org/10.1111/ajco.13124.

  20. Murray PR, Rosenthal K, Pfaller MA.Microbiología médica.. 9th ed. 2021.

  21. Ochoa-Carrillo FJ. Virus del papiloma humano.Desde su descubrimiento hasta el desarrollode una vacuna. Parte I/III. Gaceta mexicana deoncología. 2014;13(5): 308–315.

  22. Ahmed MY, Salman NA, Sandhu S, Cakir MO,Seddon AM, Kuehne C, et al. Detection of highriskHuman Papillomavirus in prostate cancerfrom a UK based population. Scientific Reports.2023;13(1): 7633. https://doi.org/10.1038/s41598-023-34734-3.

  23. McNicol PJ, Dodd JG. High prevalence of humanpapillomavirus in prostate tissues. The Journalof Urology. 1991;145(4): 850–853. https://doi.org/10.1016/s0022-5347(17)38476-8.

  24. Opeyemi Bello R, Willis-Powell L, James O,Sharma A, Marsh E, Ellis L, et al. Does HumanPapillomavirus Play a Causative Role in ProstateCancer? A Systematic Review Using BradfordHill’s Criteria. Cancers. 2023;15(15): 3897.https://doi.org/10.3390/cancers15153897.

  25. Lawson JS, Glenn WK. Evidence for a causal roleby human papillomaviruses in prostate cancer- a systematic review. Infectious Agents andCancer. 2020;15: 41. https://doi.org/10.1186/s13027-020-00305-8.

  26. Glenn WK, Ngan CC, Amos TG, Edwards RJ,Swift J, Lutze-Mann L, et al. High risk humanpapilloma viruses (HPVs) are present in benignprostate tissues before development of HPVassociated prostate cancer. Infectious Agents andCancer. 2017;12: 46. https://doi.org/10.1186/s13027-017-0157-2.

  27. Weijerman PC, König JJ, Wong ST, NiestersHG, Peehl DM. Lipofection-mediatedimmortalization of human prostatic epithelialcells of normal and malignant origin usinghuman papillomavirus type 18 DNA. CancerResearch. 1994;54(21): 5579–5583.

  28. Arriaga-Izabal D, Morales-Lazcano F,Canizalez-Román A. Human papillomavirusand prostate cancer in Mexican men: a systematicreview and meta-analysis. Cancer causes &control: CCC. 2025; https://doi.org/10.1007/s10552-025-01989-2.

  29. Sharad S, Dobi A, Srivastava S, SrinivasanA, Li H. PMEPA1 Gene Isoforms: A PotentialBiomarker and Therapeutic Target in ProstateCancer. Biomolecules. 2020;10(9): 1221. https://doi.org/10.3390/biom10091221.

  30. Sadri Nahand J, Esghaei M, HamidrezaMonavari S, Moghoofei M, Jalal Kiani S,Mostafaei S, et al. The assessment of a possiblelink between HPV-mediated inflammation,apoptosis, and angiogenesis in Prostatecancer. International Immunopharmacology.2020;88: 106913. https://doi.org/10.1016/j.intimp.2020.106913.

  31. Khatami A, Nahand JS, Kiani SJ, KhoshmirsafaM, Moghoofei M, Khanaliha K, et al. Humanpapilloma virus (HPV) and prostate cancer(PCa): The potential role of HPV geneexpression and selected cellular MiRNAs inPCa development. Microbial Pathogenesis.2022;166: 105503. https://doi.org/10.1016/j.micpath.2022.105503.

  32. Alarcón-Romero LDC, Organista-Nava J,Gómez-Gómez Y, Ortiz-Ortiz J, Hernández-Sotelo D, Del Moral-Hernández O, et al.Prevalence and Distribution of HumanPapillomavirus Genotypes (1997-2019) andTheir Association With Cervical Cancer andPrecursor Lesions in Women From SouthernMexico. Cancer Control: Journal of the MoffittCancer Center. 2022;29: 10732748221103331.https://doi.org/10.1177/10732748221103331.




2020     |     www.medigraphic.com